摘要多发性骨髓瘤是一种克隆性浆细胞恶性增殖性疾病。随着靶向治疗、CART细胞免疫、自体干细胞移植等治疗新方法的引入，多发性骨髓瘤治疗效果和患者生存期有了显著提升。同时，针对多发性骨髓瘤的诊断技术，尤其是深层次的疗效评估及预后判断的要求不断提升，对临床检验方法的敏感度及特异度有了更高的要求。本文针对多发性骨髓瘤的诊断、预后评估标准和实验室检查方法进展进行阐述。

abstractsMultiple myeloma is a clonal plasma cell malignant disorder.The treatment efficiency and overall survival rate of MM patients were significantly improved by the application of targeted therapy, chimeric antigen receptor (CAR) T-Cell Therapy and autologous stem cell transplant (ASCT). Meanwhile, the demands for newly diagnosis technologies and laboratory examination methods are required. Especially for those methods with higher sensitivity and specificity that could fit for the precise evaluation of treatment and prognosis. This review outlines the guidelines and clinical testing approaches for the diagnosis and prognosis evaluations of multiple myeloma.